Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think some longs are bailing..
Honestly, despite all the things this company has going for it, I'm tempted to as well (haven't yet, though..)
I agree with Rocket that some dramatic steps might have to be made to get some awareness out there.
In this market, the depressed big boards ARE the new penny plays, except there are no hidden financials. I love Eric as a leader and CEO, but there are just so many other opportunities out there to make money right now it's hard to watch what little money people have sit stagnant in a .0055 stock.
Hey chart - out all my CENX at 2.75.. (thanks!)
Where to put the profits? EBHI or GGP?
I might need to leave it there for 3 days while the CENX funds clear.
2.69 on CENX!
Hey GWMAN - you should include the slides from the redchip conference in that post.
I'm going to start using it as some of the 'included DD' when I post about AEMD on other boards.
I leave for my spring disc golf trip in 9 days... so psyched
Haha, maybe it was because you had ANY beer compared to none?
I know PM BxA can be a little wacky... but could someone confirm I am seeing this correctly?
CENX: 2.45 x 3.2
Thanks in advance
Looks like a Wok to me ;)
I don't have as much as some of you here, but I plan on doubling my position at these levels over the next week or so. I think we'll be getting significant news very soon.
Next step up :)
It's going to be hard not to sell once it gets back into the 2.4's giving the volatility these days.
Great news today... I'm sick of the 6's and 7's, looking forward to tomorrow.
Maybe IGA was the first of a one-two punch along with Lowes.. and they'll finish off the shorts with an uppercut on Wednesday with financials and a buyback. Pinks are for dreamers, right? :)
WNBD Lands IGA
Winning Brands From North America Begins Sales at IGA Australia
22 minutes ago - Market Wire
Related Companies
Symbol Last %Chg
WNBD 0.0070 0.00%
As of 3:35 PM ET 3/30/09
Winning Brands Corporation (PINKSHEETS: WNBD) (FRANKFURT: WMU) www.WinningBrands.ca reports that its breakthrough stain removing solution, Winning Colours Stain Remover, is now officially on the shelves and running in Australia's grocery sector. In a neck and neck race as to who would be first, Coco's Fresh Food Markets and IGA both have earned the praise of Winning Colours Australia Ambassador Kori Walsh. "The first bottles were delivered to Coco's Fresh Food Markets while IGA is also taking a leadership role; they both want Australians to find their own favourite uses for this intriguing new product from North America. Both teams are highly responsive to the needs of their consumers. I must say, I am pretty happy with the first week's results," Kori states enthusiastically. (IGA Photos attached).
In Australia, Winning Brands will focus initial sales development on the State of Queensland in order for Winning Colours Stain Remover to gain solid experience and feedback from consumers and retailers before going national. Of the current grocery partners, IGA already has the ability to carry the program across Australia in due course, where approximately 1,000 stores operate under that banner. (www.iga.net.au) Internationally, the IGA organization has approximately 4,000 stores including the United States and Canada amongst other countries. Winning Colours Stain Remover has also implemented an Australian national toll-free number for customer service purposes: 1 300 506 607.
In February 2009 Winning Brands announced that its second shipment of Winning Colours Stain Remover was leaving the U.S. for Australia to commence initial grocery store sales in Australia Q2 2009, however the participating grocers were not yet named. As of today, the project is ahead of schedule with product now on shelves in participating stores in the State of Queensland. Walsh confirms that even the February shipment of Winning Colours to Australia ended up being largely sold in advance despite having been doubled in size at the last moment before departure to approximately 2 tons of skids of mixed sizes. A 3rd shipment is now a matter of immediate priority. "We have 19 more IGA stores committed and awaiting the arrival of the 125ml bottle to round out the product mix between large and small sizes. Approximately 40 more stores will provide feedback regarding next steps in April," Kori states.
In Australia, the Manufacturer's Suggested Retail Price (MSRP) for the Winning Colours Stain Remover 909ml bottle, including tax, is AUD $16.95. This is an approximate transfer of the MSRP U.S. $9.95 + tax from the United States at prevailing rates of currency exchange; U.S. sales tax rates vary. This pricing enables Australians to enjoy Winning Colours Stain Remover at approximately the same value proposition as North American consumers. The fact that Winning Colours is a concentrated product means that it has become one of the world's most affordable high-quality cleaning products at a 10:1 rate of dilution with water, as well as being competitively priced within the stain removing sector where Winning Colours Stain Remover is used full-strength. The ability of Winning Colours Stain Remover to switch between being a concentrated stain remover and a diluted general purpose multi-cleaner has helped the product gain a devoted following in Canada and increasingly the USA.
Winning Colours Stain Remover is considered remarkable for its gentleness to skin and is winning acclaim from a wide range of consumers, both household and commercial, for its versatility. YouTube now carries a recently completed 4-minute Winning Colours Stain Remover highlight video designed for retailers in the hardware sector:
Is it just scottrade or is everyone showing almost 1/3 of the daily avg. volume traded over the first 20 minutes today?
Nice dialogue over the weekend, I'm glad I have you guys around. It will get very exciting around here, me thinks.
That being said, .27 hit!
GM All,
I went to several health food stores in the Cambridge, MA area this weekend and inquired about this product that had been recommended to me for a particular job I have to clean up... something called Winning Colors or something. Many of the managers were very receptive to the iquiry. I left company contact info with four stores.
Most of the stores already had many potential competitors on the shelf. One manager just showed me where those were, but I told him a few of those that I had tried hadn't worked (true), and that I wanted to be able to buy Winning Colors locally.
The only fib I told was that I was actually the one recommending the product to myself. Oops.
I know it's small but I'll follow up with them in the coming weeks.
Welcome, Philife!
I'd be great to get the rest of the 20 long's who've had it boardmarked for quite some time to come out of the wood work and get this thing moving :)
AEMD has a very exciting future ahead of itself.
News Release
View printer-friendly version
<< Back
Delcath and Aethlon Medical Sign Collaboration Agreement to Research and Develop Advanced Filtration Technology
SAN DIEGO & NEW YORK, Jan 30, 2008 (BUSINESS WIRE) -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease and advanced blood filtration, and Delcath Systems, Inc. (NASDAQ:DCTH), a development stage company focused on developing and marketing a proprietary drug delivery system, today announced a collaboration to jointly research and develop an advanced filtration cartridge for potential use in Delcath Systems' percutaneous hepatic perfusion ("PHP") system. PHP is a technology designed to isolate and deliver high doses of anti-cancer agents to specific organs or regions of the body, while minimizing the exposure of the drugs to the rest of the body.
Under the terms of the agreement, Aethlon Medical is researching and developing a hybrid filter technology capable of removing traditional anti-cancer agents, as well as newer drug agents that may not be candidates for traditional carbon-based filters, from the blood. Delcath will fund the initial stage of this collaboration through the purchase of 100,000 Aethlon Medical common shares at $1.00 per share.
Commenting on the agreement, Richard Taney, President and CEO of Delcath, stated, "We continue seeking ways to improve and extend the applications for Delcath's platform technology. Recent advances in filtration technologies make this an area of focus for our company as we seek to expand the potential applications for the Delcath System. Activated carbon is a very efficient broad-spectrum filter medium for the majority of anti-cancer agents, but we continue to investigate novel technologies that will enable physicians to use our system with additional drugs. By funding this collaboration, we establish a relationship with one of the leading innovators in the area of blood filtration and extend our proprietary advantage. Aethlon has demonstrated expertise in advanced filtration technologies and is well positioned to assist us in this endeavor."
"We are honored to have the opportunity to work with Delcath in advancing their unique platform technology towards the goal of improved clinical outcomes for cancer patients," stated James A. Joyce, Chairman and CEO of Aethlon Medical. "The Delcath relationship also provides the possibility of expanding our product pipeline by developing and supplying a therapeutic application not targeted by our Hemopurifier(R)," concluded Joyce.
About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of 28 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.
About Aethlon Medical, Inc.
Aethlon Medical is the developer of the Hemopurifier(R), a first-in-class medical device designed to treat infectious disease. The Hemopurifier(R) provides real-time therapeutic filtration of infectious viruses, toxins, and immunosuppressive particles, and is positioned to address the largest opportunity in infectious disease, the treatment of drug and vaccine resistant viruses. The device also holds promise in cancer care, as research studies have verified the capability of the Hemopurifier(R) to rapidly remove immunosuppressive particles that are secreted by tumors. The Hemopurifier(R) is targeted for use a stand-alone therapeutic, and as an adjunct treatment able to improve the clinical benefit of established and candidate therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier(R) in capturing pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. Studies are also being conducted to support the use of the Hemopurifier(R) as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has previously demonstrated safety of the Hemopurifier(R) in a 24-treatment human study at the Apollo Hospital in Delhi, India, and is currently conducting further human studies at the Fortis Hospital, also located in Delhi. The Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) related to advancing the Hemopurifier(R) as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier(R) technology is available online at www.aethlonmedical.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.
SOURCE: Aethlon Medical, Inc.
Aethlon Medical, Inc.
Jeff Richardson
Senior Director, Communications
858-459-7800 x302, jrichardson@aethlonmedical.com or
Delcath Systems, Inc.
Richard Taney, 212-489-2100
www.delcath.com or
Argot Partners LLC
Andrea Rabney
andrea@argotpartners.com
News Release
View printer-friendly version
<< Back
Aethlon Medical Completes First Medical Device Study to Treat HIV/AIDS
SAN DIEGO--(BUSINESS WIRE)--Jan. 26, 2009--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has completed the "first-in-man" study of a medical device to treat Human Immunodeficiency Virus (HIV), the disease that causes Acquired Immune Deficiency Syndrome (AIDS). In the study, an HIV-infected individual completed a twelve treatment study of the Aethlon Hemopurifier(R) administered thrice weekly over the course of 30-days. The Hemopurifier(R) is a therapeutic filtration device that serves as an artificial adjunct to the immune system. In HIV care the Hemopurifier(R) targets the clearance of all circulating strains of infectious HIV, including those varieties that cause patients to fail antiviral drug regimens. Additionally, the device assists to preserve immune response through the removal of gp120 and other toxic proteins shed by HIV to kill-off immune cells, the hallmark of AIDS. The study was conducted at the Sigma New Life Hospital in Punjab, India. Initial viral load and immune cell data resulting from the study are expected to be available for disclosure in mid-February.
"Based on previous treatment outcomes in Hepatitis-C patients, we are cautiously optimistic that the data resulting from our first HIV study will also prove to be positive," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "The principal investigator of our study has reported all twelve Hemopurifier(R) treatments were completed without any observed adverse events, and that the patient feels an improved sense of well being, including increased energy and appetite," concluded Joyce.
In a previous infectious disease study, treatment with the Hemopurifier(R) resulted in robust viral load reductions in Hepatitis-C (HCV) infected patients who completed a treatment protocol of three, 4-hour Hemopurifier(R) treatments every other day during the course of one week. The Study was conducted at the Fortis Hospital in Delhi, India.
Patient #1 had a 95% reduction three days post treatment and 89% reduction seven days post treatment. The initial viral load for patient 1 was 5.3 x 10(5) viral units per ml of blood (IU/ml). Patient 1's viral load seven days post treatment was 5.7 x 10(4) IU/ml.
Patient #2 had a 85% reduction three days post treatment and 50% reduction seven days post treatment. The initial viral load for patient 2 was 9.2 x 10(6) IU/ml. Patient 2's viral load seven days post treatment was 4.6 x 10(6) IU/ml.
Patient #3 had a 60% reduction three days post treatment and 83% reduction seven days post treatment. The initial viral load for patient 3 was 3.0 x 10(8) IU/ml. Patient 3's viral load seven days post treatment was 5.1 x 10(7) IU/ml. All viral load measurements were performed with real-time quantitative polymerase chain reaction (RT-PCR). Control samples were measured in duplicate while treatment samples were generally measured in triplicate.
About Aethlon Medical
Aethlon Medical is the developer of the Hemopurifier(R), a first-in-class medical device designed to treat infectious disease. The Hemopurifier(R) provides real-time therapeutic filtration of infectious viruses and immunosuppressive particles, and is positioned to address the treatment of drug and vaccine resistant viruses. Additionally, the device holds promise in cancer care, as research studies have verified the Hemopurifier(R) is able to capture immunosuppressive particles secreted by tumors. The Hemopurifier(R) is designed to act both as a stand-alone therapeutic, and as an adjunct treatment to enhance clinical benefit of established therapies. Pre-clinical studies conducted by researchers representing leading government and non-government health organizations both in the United States and abroad have documented the effectiveness of the Hemopurifier(R) in capturing from circulation the viruses that constitute pandemic threats, including H5N1 Avian Influenza (bird flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company is conducting studies to support the use of the Hemopurifier(R) as a broad-spectrum treatment countermeasure against bioterror threats, including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States have been focused on bioterror threats, while international initiatives are directed toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon has demonstrated safety of the Hemopurifier(R) in a 24-treatment human study at the Apollo Hospital in Delhi, India, and in an 18-treatment study at the Fortis Hospital, also located in Delhi. The company has also submitted an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to advance the Hemopurifier(R) as a broad-spectrum treatment countermeasure against category "A" bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifier(R) technology is available online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
CONTACT: Aethlon Medical, Inc.
Jim Frakes, Senior VP Finance
858-459-7800 x300
jfrakes@aethlonmedical.com or
Jim Joyce, Chairman, CEO
858-459-7800 x301
jj@aethlonmedical.com
Source: Aethlon Medical, Inc.
Welcome...
Not necessarily a one trick pony:
News Release
Aethlon Medical Announces Expansion Into the Infectious Disease Diagnostic Market
SAN DIEGO--(BUSINESS WIRE)--Feb. 10, 2009-- Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has expanded the applications of its Hemopurifier® platform technology to address voids in the infectious disease diagnostic market. The Aethlon Hemopurifier® is a first-in-class artificial adjunct to the immune system able to provide real-time capture of infectious viruses and immunosuppressive particles from the entire circulatory system. The device is a leading broad-spectrum treatment candidate for acute and chronic virus infections. Scientific techniques that established the therapeutic potential of the Hemopurifier® will be leveraged to introduce ultra-sensitive clinical and research diagnostic tools that offer significant potential for previously unrecognized revenue channels.
In diagnostic applications, Aethlon will concentrate viruses from large blood volumes to increase sensitivity of viral load testing standards, which previously have been limited to detecting viruses from small blood samples. By concentrating virus directly from a patient or from donated blood units, the sensitivity of viral load tests may be increased up to 5,000 fold as compared to 1ml blood sample testing. Thus allowing for the accurate detection of viruses such as HIV and HCV even when viral load may be deemed undetectable through current testing standards. Additional market opportunities include the identification of viral pathogens that trigger the rejection of stem-cell therapies, bone marrow, and organ transplants. Upon confirmation of such viruses, the Hemopurifier® would then become a treatment candidate to improve stem-cell therapy and transplant outcomes. Aethlon’s diagnostic techniques would provide superior detection of viruses in donated blood and may unlock the ability for researchers to discover viral biomarkers that underlie a multitude of disease conditions. Aethlon also disclosed its diagnostic capabilities will be deployed to further reinforce the therapeutic benefit of the Hemopurifier® to capture deleterious viruses from circulation. In this regard, Aethlon has initiated a diagnostic program to screen and identify all viral species captured in the recent Hemopurifier® treatment of a Hepatitis-C infected patient.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic filtration devices to improve the health of individuals afflicted with infectious disease and cancer. The Company’s lead product, the Aethlon Hemopurifer®, is a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from circulation. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier® also holds promise in cancer care, as research studies verify the Hemopurifier® effectively captures immunosuppressive exosomes that are secreted by tumors to kill-off immune cells. At present, over sixty (60) Hemopurifier® treatments (representing approximately 240 hours of treatment time) have been conducted in multi-site studies at the Apollo Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The studies enrolled end-stage renal disease (ESRD) patients infected with either HCV or HIV. In addition to establishing treatment safety, robust viral load reductions have been reported in HCV-infected patients who completed a three-treatment protocol during the course of one week.
Research studies have also demonstrated the Hemopurifier® is effective in capturing a broad-spectrum of viruses untreatable with drug therapy, including several of world’s deadliest bioterror and pandemic threats. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV), and Vaccinia and Monkeypox (MPV), which both serve as models for human smallpox infection. The studies were conducted with the assistance of researchers representing: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID); The Centers for Disease Control and Prevention (CDC); The National Institute of Virology (NIV); The Battelle Biomedical Research Center (BBRC); and The Southwest Foundation for Biomedical Research (SFBR).
In additional to therapeutic market opportunities, Aethlon is leveraging principles underlying the Hemopurifier® technology platform to establish a pipeline of clinical and research diagnostic products and services. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company’s ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings.
Source: Aethlon Medical, Inc.
Aethlon Medical, Inc.
Prashant Mehta, Ph.D.
Director of Business Development
858-459-7800 x303
pmehta@aethlonmedical.com
or
Jim Frakes
Senior VP Finance
858-459-7800 x300
jfrakes@aethlonmedical.com
or
Jim Joyce
Chairman, CEO
858-459-7800 x301
jj@aethlonmedical.com
So what attracted you to AEMD?
disposable cartridges, implications to help treat cancer, HIV, Dengue, Ebola, Bird Flu, HCV, etc etc
Commercialization and subsequent initial income is a milestone
Extensive R+D since inception
Commercialization since 2009
haha, deal
Sounds crazy but I totally agree.
Awesome rebound today.
Thanks for the heads up.
YAWWWWWWWNN
Good Morning Everyone :)
That's a lot of shares ;)
.25 on the ask!!
I hope you're bringing some of those WU gains over here like I have been :)
Didn't take much...
and to think there are only 20 boardmarks.
Hey guys, put AEMD on your watch lists, it might be starting to make a move, and if it does, I don't think it'll look back, IMO.
Nice buys. I wish I had enough free capital to add like that :)
Someday after a few forward splits we'll all be buying eachother a round.
When there's interest, this thing flies... barely any messing around between the pennies.
CENX
2.42 hit, could break loose
The 1 year chart sure does look damn sexy!
Here's to a good 2009.
CENX making a push going into the close?
That's ok. I saw the word commercialization, that's all I need :)